• Nutrition Research and Practice
• /
• 제14권2호
• /
• pp.102-108
• /
• 2020

BACKGROUND/OBJECTIVES: In Oriental medicine, certain foods may be beneficial or detrimental based on an individual's constitution; however, the scientific basis for this theory is insufficient. The purpose of this study was to investigate the effect of body constitution, based on the Sasang type of Korean traditional medical classification system, on the bioavailability of soy isoflavones of Cheonggukjang, a quick-fermented soybean paste. SUBJECTS/METHODS: A pilot study was conducted on 48 healthy Korean men to evaluate the bioavailability of isoflavone after ingestion of food based on constitution types classified by the Sasang typology. The participants were classified into the Taeeumin (TE; n = 15), Soyangin (SY; n = 15), and Soeumin (SE; n = 18) groups. Each participant ingested 50 g of Cheonggukjang per 60 kg body weight. Thereafter, blood was collected, and the soy isoflavone metabolites were analyzed by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. Ntrikinetic analysis of individual isoflavone-derived metabolites was performed. RESULTS: Our nutrikinetic analysis identified 21 metabolites derived from isoflavones in the blood samples from 48 healthy Korean men (age range, 21-29 years). Significant differences were observed in the time to maximum concentration (T_max) and elimination half-life (t_1/2) for nine metabolites among the three groups. The T_max and t_1/2 of the nine metabolites were higher in the SE group than in the other groups. Moreover, the absorption rates, as determined by the area under the plasma-level curve (AUC) values of intact isoflavone, were 5.3 and 9.4 times higher in the TE group than in the SY and SE groups, respectively. Additionally, the highest AUC values for phase I and II metabolites were observed in the TE group. CONCLUSIONS: These findings indicate that isoflavone bioavailability, following Cheonggukjang insgestion, is high in individuals with the TE constitution, and relatively lower in those with the SE and SY constitutions.

• 대한기계학회논문집B
• /
• 제39권12호
• /
• pp.927-934
• /
• 2015

고일사 지역인 사우디아라비아에서 태양열로 구동하는 흡수식 냉동 시스템 개발을 염두에 두고, 본 논문에서는 태양을 추적하는 선형 프레넬 반사판 시스템의 집광 특성을 수치해석 하였다. 몬테카를로 광선추적법을 기반으로 하는 광학 프로그램을 통해 집광 열유속, 집광 효율, 집광 에너지를 일년을 대표하는 춘분, 하지, 추분, 동지 날짜에 계산하였다. 동지를 제외하면, 9 시에서 15 시까지는 집광 성능이 일정한 가운데, 집광 효율도 70% 이상으로 높게 나타났다. 이 시간대에서 흡수기 중심 20% 영역에 모이는 최대 열유속은 하지 때 약 $13.0{\sim}14.6kW/m^2$ 범위에서 변했다. 집광 시스템의 설계 인자 중에서 흡수기 설치 높이, 반사판의 폭, 반사판 사이의 거리가 집광 효율을 조사해 보면, 흡수기 설치 높이는 반사판의 폭에 관계없이 5 m 에서 최적의 성능을 나타냈다. 반사판의 폭이 작을수록 집광 효율이 좋지만, 반사판의 폭은 집광 되는 에너지에 직접적으로 비례하기 때문에 냉동 시스템의 용량에 맞추어 설계가 필요하다. 본 연구는 흡수기의 열전달 해석의 중요한 선행조건이므로 향후에 광학-열전달 연계된 해석을 통해 전체 시스템의 성능을 예측하고 설계하는데 활용할 수 있을 것이다.

• Journal of the Korean Wood Science and Technology
• /
• 제41권4호
• /
• pp.293-301
• /
• 2013

본 연구에서는 수분 흡착효과가 있다고 알려진 커피박을 첨가하여 중밀도섬유판을 제조한 다음 물성과 강도특성을 조사하여 커피박의 중밀도섬유판 원료로써의 가능성을 확인하고자 하였다. 커피박은 주로 인스턴트커피 제조 시 많이 발생하는 찌꺼기인데 가수분해된 것을 전건무게 기준 3, 6, 9% 수준에서 목섬유와 혼합해 중밀도섬유판을 제조하였으며, 이 때 사용한 접착제는 요소수지접착제였다. 커피박과 목섬유를 섞은 중밀도섬유판에 대해 물성과 강도 특성 및 포름알데히드 방산량을 측정하였다. 커피박과 목섬유를 무작위로 섞어 제조한 중밀도섬유판의 휨강도와 박리강도는 모두 KS 기준보다 높게 나타났으며 커피박을 층으로 구성한 적층 성형구조 경우에는 모두 기준에 미달하였다. 제조된 중밀도섬유판의 흡수 두께팽창률은 시판용 중밀도섬유판보다 낮아 물리적 특성 면에서 현저히 개선됨을 보여주었다. 포름알데히드 방산량은 시판용 중밀도섬유판과 유사한 것으로 나타났으며 모두 KS 기준상의 $E_1$급에 부합하였다. 이런 결과는 커피박이 친환경 중밀도섬유판 제조 시 원재료로 활용될 수 있음을 보여주고 있으며 중밀도섬유판의 성능 향상을 위해서는 접착제와 커피박 간의 상호 접착성 및 커피박의 흡착성능 향상을 위한 전환방법에 대한 추가 연구가 요구된다.

• 대한환경공학회지
• /
• 제35권5호
• /
• pp.340-349
• /
• 2013

본 연구에서는 해수를 이용하여 석탄 화력발전소에서 발생하는 $CO_2$를 포집하기 위해 발전소에서 수급이 용이한 비산재, NaOH, $Ca(OH)_2$를 해수에 첨가하여 제조된 흡수제의 $CO_2$ 포집 성능을 고찰하였다. 비산재가 첨가된 해수의 $CO_2$ 포집성능은 순 해수에 비해 높아 비산재의 $CO_2$ 포집 효과는 유효하다. 그러나 해수 내 다양한 이온들에 의해 증류수에서 보다 비산재 내 유효 성분들의 침출량과 침출속도가 제한적이다. NaOH가 첨가된 해수는 $OH^-$ 손실이 일어나 증류수에 비해 $CO_2$ 포집량이 낮았고 다양한 이온의 상호 작용에 의해 포집 속도가 낮았다. $Ca(OH)_2$를 첨가한 경우, 해수에서의 $CO_2$ 포집 성능은 증류수 보다 높았는데 이는 해수 내 이미 존재하고 있던 $Ca^{2+}$ 중 일부가 탄산화 반응에 참여했기 때문으로 판단된다.

• Journal of Pharmaceutical Investigation
• /
• 제34권5호
• /
• pp.413-418
• /
• 2004

A bioequivalence of $Melax^{TM}$ capsules (Chong Kun Dang Pharm., Korea) and $Mobic^{TM}$ capsules (Boehringer Ingelheim Korea) was evaluated according to the guideline of Korea Food and Drug Administration (KFDA). Single 15 mg dose of meloxicam of each medicine was administered orally to 24 healthy male volunteers. This study was performed in a $2\;{\times}\;2$ crossover design. Concentrations of meloxicam in human plasma were monitored by a high-performance liquid chromatography. $AUC_t$ (the area under the plasma concentration-time curve from time zero to 72 hr) was calculated by the linear trapezoidal rule method. $C_{max}$ (maximum plasma drug concentration) and $T_{max}$ (time to reach $C_{max}$) were compiled from the plasma concentration-time data. Analysis of variance was performed using logarithmically transformed $AUC_t$ and $C_{max}$. No significant sequence effect was found for all of the bioavailability parameters. The 90% confidence intervals of the $AUC_t$ ratio and the $C_{max}$ ratio for $Melax^{TM}/Mobic^{TM}$ were 0.95 - 1.04 and 0.98 - 1.14, respectively. This study demonstrated a bioequivalence of $Melax^{TM}$ and $Mobic^{TM}$ with respect to the rate and extent of absorption.

• 한국산학기술학회논문지
• /
• 제19권1호
• /
• pp.603-608
• /
• 2018

전압 인가식 제전방식이 반도체나 디스플레이 산업에는 가장 많이 사용되고 있지만, 방전에 의한 주변 미세 먼지의 흡착 및 전극핀의 오염으로 불량 발생의 원인을 제공하므로, 주기적인 관리 비용이 발생하게 된다. 전극핀의 오염 문제는 코로나 방전으로 인하여, 주변 공기의 미세한 입자를 축적함으로 생성된다. Fuzz ball의 생성은 전극핀의 마모를 촉진 시키고, 또한 정전기 제거 장치의 성능을 저하시킨다. 오염물 제거 방법은 수동 브러쉬 및 자동 브러쉬를 이용하여 기계적인 세척 방법이 효과적이지만, 추가적인 기계부품이나 사용자의 관리를 요구한다. 일부의 경우에는 이미터에 축척된 오염물이 웨이퍼나 제품에 전이될 수도 있다. 이러한 문제를 해결하기 위해, 제전기의 외부로 돌출되는 전극핀을 없애고, 이온탱크 내부에 위치한 텡스텐 전극선을 이용하여 주위 기체 분자를 직접 이온화할 수 있는 청정 환경에 적합한 정전기 제거 장치를 개발하였다. 한국기계연구원에서 시험인증한 결과, 오염 입자는 평균 $0.7572particles/ft^3$이고, 제전 시간은 2초 이하 이며, 잔류 전위는 7.6V로 만족할 만한 결과를 얻었다.

• Journal of Pharmaceutical Investigation
• /
• 제36권2호
• /
• pp.137-142
• /
• 2006

A bioequivalence of Daewoong $Alendronate^{TM}$ (Daewoong Pharmaceutical Co., Ltd., Korea) and $Fosamax^{TM}$ tablets (MSD Korea) was evaluated according to the guideline of Korea Food and Drug Administration (KFDA). A single 70 mg dose of sodium alendronate of each medicine was administered orally to 56 healthy male volunteers. This study was performed in a $2\;{\time}\;2$ crossover design. Concentrations of alendronate in the urine were monitored by a high-performance liquid chromatography (HPLC). $A_{et}$ (cumulative urinary excreted amount from time 0 to last sampling interval) was calculated by the accumulation of the urinary excreted alendronate. $U_{max}$ (maximum urinary excretion rate) and $T_{max}$ (time to reach $U_{max}$) were compiled from the urinary excretion rate - time data. Analysis of variance was performed using logarithmically transformed $A_{et}$ and $U_{max}$. No significant sequence effect was found for all of the bioavailability parameters. The 90% confidence intervals of the $A_{et}$ and $U_{max}$ for Daewoong $Alendronate^{TM}/Fosamax^{TM}$ were 0.89-1.12 and 0.82-1.02, respectively. This study demonstrated the bioequivalence of Daewoong $Alendronate^{TM}$ and $Fosamax^{TM}$ with respect to the rate and extent of absorption.

• Journal of Pharmaceutical Investigation
• /
• 제37권4호
• /
• pp.255-261
• /
• 2007

A bioequivalence study of $Nimegen^{TM}$ soft capsule (Medica Korea Pharma. Co., Ltd.) to $RoAccutane^{(R)}$ soft capsule (Roche Korea Ind. Co., Ltd.) was conducted according to the guidelines of Korea Food and Drug Administration (KFDA). Thirty healthy male Korean volunteers received each medicine at the isotretinoin dose of 60 mg in a $2{\times}2$ crossover study. There was one week wash-out period between the doses. Plasma concentrations of isotretinoin were monitored by a high performance liquid chromatography (HPLC) for over a period of 48 hours after drug administration. $AUC_t$ (the area under the plasma concentration-time curve from time zero to 48 hr) was calculated by the linear trapezoidal rule method. $C_{MAX}$ (maximum plasma drug concentration) and $T_{MAX}$ (time to reach $C_{MAX}$) were compiled from the plasma concentration-time data. Analysis of variance was carried out using logarithmically transformed $AUC_t\;and\;C_{MAX}$. No significant sequence effect was found for all of the bioavailability parameters indicating that the crossover design was properly performed. The 90% confidence intervals of the $AUC_t$ ratio and the $C_{MAX}$ ratio for $Nimegen^{TM}/RoAccutane^{(R)}$ were $log0.860{\sim}log0.98\;and\;log0.85{\sim}log1.00$, respectively. These values were within the acceptable bioequivalence intervals of $log0.80{\sim}log1.25$. Thus, our study demonstrated the bioequivalence of $Nimegen^{TM}\;and\;RoAccutane^{(R)}$ with respect to the rate and extent of absorption.

• Journal of Pharmaceutical Investigation
• /
• 제39권2호
• /
• pp.133-139
• /
• 2009

The purpose of the present study was to evaluate the bioequivalence of two pioglitazone HCl tablets, $Actos^{TM}$, tablets (Lilly Korea. Ltd., Korea) as a reference drug and $Piros^{TM}$, tablets (Reyon Pharm. Co., Ltd., Korea) as test drug, according to the guideline of Korea Food and Drug Administration (KFDA). Twenty-four healthy male Korean volunteers received one tablet containing pioglitazone HCl 15 mg in a $2{\times}2$ crossover study. There was a one-week washout period between the doses. Plasma concentrations of pioglitazone were monitored for over a period of 36 hr after administration by using a high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS). The area under the plasma concentration-time curve from time zero to 36 hr ($AUC_{0-36hr}$), maximum plasma drug concentration ($C_{max}$) and time to reach $C_{max}$ ($T_{max}$) were complied from the plasma concentration-time data. Analysis of variance (ANOVA) test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_{0-36hr}$ and $C_{max}$. The 90% confidence intervals of the $AUC_{0-36hr}$ ratio and the $C_{max}$ ratio for $Piros^{TM}$/$Actos^{TM}$. were log 0.8753-log 1.1286 and log 0.8669-log 1.1734, respectively. These values were within the acceptable bioequivalence intervals of log 0.80-log 1.25, recommended by KFDA. In all of these results, we concluded that the $Piros^{TM}$. tablet was bioequivalent to the $Actos^{TM}$. tablet, based on the rate and extent of absorption.

• Journal of Pharmaceutical Investigation
• /
• 제39권6호
• /
• pp.457-463
• /
• 2009

The purpose of the present study was to evaluate the bioequivalence of meloxicam capsule, $Mobic^{TM}$ capsule( Boehringer Ingelheim Ltd., Korea) as a reference drug and $Meloxifen^{TM}$ capsule (Kukje Pharma Ind. Co., Ltd., Korea) as a test drug, according to the guidelines of Korea Food and Drug Administration(KFDA). Thirty two healthy male Korean volunteers received capsule containing meloxicam 7.5 mg in a $2{\times}2$ crossover study. There was a one-week above washout period between the doses. Plasma concentrations of meloxicam were monitored for over a period of 72 hr after administration by using a high performance liquid chromatography-tandem mass spectrometer(LC-MS/MS). $AUC_t$(the area under the plasma concentration-time curve from time zero to 72 hr), $C_{max}$(maximum plasma drug concentration) and $T_{max}$(time to reach $C_{max}$) were complied from the plasma concentration-time data. Analysis of variance(ANOVA) test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t$ and $C_{max}$. The 90% confidence intervals of the $AUC_t$ ratio and the $C_{max}$ ratio for $Meloxifen^{TM}/Mobic^{TM}$ were log 0.8605-log 0.9847 and log 0.9765-log 1.1503, respectively. These values were within the acceptable bioequivalence intervals of log 0.80-log 1.25, recommended by KFDA. In all of these results, we concluded that $Meloxifen^{TM}$ capsule was bioequivalent to $Mobic^{TM}$ capsule, based on the rate and extent of absorption.